Terminated cancer drug combo trial sought right dose

This early-stage trial aimed to find a safe and effective dose for combining two oral cancer drugs (tuvusertib and PLX038) in patients with advanced solid tumors that had stopped responding to standard treatments. The study first tested different dose combinations in a small group to check for safety, then planned to expand to test effectiveness in specific cancer types like triple-negative breast cancer. The trial was terminated early after enrolling only 10 patients.